论文部分内容阅读
目的 比较点突变p5 3及其抗原肽重组痘苗病毒诱导的抗瘤免疫反应 ,为重组抗原疫苗用于肿瘤免疫治疗提供实验依据。方法 以人 135位Cys→Tyr点突变 p5 3为肿瘤相关抗原模型 ,观察以表达该点突变 p5 3蛋白的重组痘苗病毒rVV p5 3FL与表达包含该点突变抗原肽 p5 312 5 14 5的重组痘苗病毒rVV p5 3M 所诱导的CTL及对荷瘤Balb/c小鼠的免疫保护和治疗作用。结果 rVV p5 3FL和rVV p5 3M 均能诱导以CD8+T细胞为主的特异性CTL。用rVV p5 3FL与rVV p5 3M 免疫小鼠后 ,接种致死剂量的P815 mp5 3细胞 ,能保护部分小鼠免遭致死剂量肿瘤细胞的攻击。小鼠接种致死剂量的肿瘤细胞后 ,以rVV p5 3FL与rVV p5 3M 治疗荷瘤小鼠 ,可使小鼠平均存活时间显著延长。两种疫苗的抗瘤效应无明显区别。结论 来源于突变p5 3的抗原肽重组疫苗 ,可代替抗原大分子应用于肿瘤的免疫防治
OBJECTIVE: To compare the anti-tumor immune response induced by recombinant p153 and its antigen peptide recombinant vaccinia virus, and to provide experimental evidence for recombinant antigen vaccine for tumor immunotherapy. Methods A human tumor-associated antigen (C5 → Tyr point mutation p5 3) was used as a model of tumor-associated antigen. The recombinant vaccinia virus (pVV) p5 3FL expressing the point mutation p5 3 protein and the recombinant vaccinia virus expressing the point mutation antigen peptide p5 312 5 14 5 CTL induced by virus rVV p5 3M and its immunoprotective and therapeutic effects on tumor-bearing Balb / c mice. Results Both rVV p5 3FL and rVV p5 3M could induce CD8 + T cell-specific CTL. Inoculation of lethal doses of P815 mp5 3 cells after immunization of mice with rVV p5 3FL and rVV p5 3M protected some mice from lethal doses of tumor cells. After mice were inoculated with lethal doses of tumor cells, the treatment of tumor-bearing mice with rVV p5 3FL and rVV p5 3M significantly prolonged the mean survival time in mice. The anti-tumor effect of the two vaccines no significant difference. Conclusions Recombinant vaccine of antigen peptide derived from mutant p5 3 can replace immunized macrophages in immunotherapy of tumors